UNSPSC 51314335: Chlorpheniramine/dextromethorphan/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.

UNSPSC 51314335 Chlorpheniramine/dextromethorphan/phenylpropanolamine is a Commodity code that captures state and local procurement of specific pharmaceutical products, though recent state and local opportunities solicited under this code do not align with its nominal scope. The three recent opportunities in the block target naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer prescription fulfillment capabilities—none of which are the specific combination product named in the code. State and local governments using this code appear to be acquiring a broader range of pharmaceutical and health-related products than the code's narrow chemical composition suggests, reflecting how jurisdictions sometimes apply UNSPSC tags that do not precisely match procurement work. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances serving state and local end-users.

Recent opportunities span Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer pharmacy programs before formal competitive solicitation. The Minnesota Department of Administration's Office of State Procurement, administering the MMCAP cooperative purchasing alliance, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with responses due March 26, 2026, and contract performance beginning July 1, 2026. The Minnesota RFP emphasizes price competitiveness (75 percent evaluation weight), FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, and established relationships with three authorized wholesalers. Vendors should note that this code shows low relevance to its stated pharmaceutical product scope based on current solicitation activity.